aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update

Provided By GlobeNewswire

Last update: May 2, 2024

Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected to complete enrollment in the second quarter of 2024.

Ended the first quarter 2024 with $87.7 million in cash, cash equivalents, restricted cash and investments.